Literature DB >> 12162500

Autosomal dominant hypocalcemia caused by a novel mutation in the loop 2 region of the human calcium receptor extracellular domain.

Jianxin Hu1, Stefano Mora, Giacomo Colussi, Maria Carla Proverbio, Kendra A Jones, Laura Bolzoni, Maria E De Ferrari, Giovanni Civati, Allen M Spiegel.   

Abstract

We report a novel missense mutation N124K in the extracellular calcium receptor (CaR) identified in two related subjects with the phenotypic features of autosomal dominant hypocalcemia (ADH). Expression of the N124K mutant receptor created by site-directed mutagenesis and transfected into HEK-293 cells was comparable with that of the wild-type (WT) receptor and two other mutant receptors N118K and L125P identified in subjects with ADH. Functional characterization by the extracellular Ca2+ ion ([Ca2+]0)-stimulated phosphoinositide (PI) hydrolysis in transfected HEK-293 cells showed that the N124K mutant receptor was left-shifted in Ca2+ sensitivity. This biochemical gain-of-function is comparable with that seen in other missense mutations of the CaR identified in subjects with ADH. We tested a series of missense substitutions (R, Q, E, and G) in addition to K for N124 and found that only the N124K mutation and to a much lesser extent N124R caused a left shift in Ca2+ sensitivity. Thus, a specific substitution, not merely a mutation of the N124 residue, is required for receptor activation. The N124K mutation is one of eight naturally occurring mutations in subjects with ADH identified in a short segment A116-C129 of the CaR extracellular domain (ECD). We present a hypothesis to explain receptor activation by mutations in this region based on the recently described three-dimensional structure of the related metabotropic glutamate type 1 receptor (mGluR1).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162500     DOI: 10.1359/jbmr.2002.17.8.1461

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator.

Authors:  Jianxin Hu; Guadalupe Reyes-Cruz; Wangzhong Chen; Kenneth A Jacobson; Allen M Spiegel
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

Review 2.  Autosomal dominant hypocalcemia with a novel CASR mutation: a case study and literature review.

Authors:  Yingying Wu; Chao Zhang; Xiaojun Huang; Li Cao; Shihua Liu; Ping Zhong
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

3.  Multiple Ca(2+)-binding sites in the extracellular domain of the Ca(2+)-sensing receptor corresponding to cooperative Ca(2+) response.

Authors:  Yun Huang; Yubin Zhou; Adriana Castiblanco; Wei Yang; Edward M Brown; Jenny J Yang
Journal:  Biochemistry       Date:  2009-01-20       Impact factor: 3.162

4.  Allosteric Modulation of G Protein Coupled Receptors by Cytoplasmic, Transmembrane and Extracellular Ligands.

Authors:  Naveena Yanamala; Judith Klein-Seetharaman
Journal:  Pharmaceuticals (Basel)       Date:  2010-10-01

Review 5.  Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators.

Authors:  Jianxin Hu; Allen M Spiegel
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

6.  Excessive signal transduction of gain-of-function variants of the calcium-sensing receptor (CaSR) are associated with increased ER to cytosol calcium gradient.

Authors:  Marianna Ranieri; Grazia Tamma; Annarita Di Mise; Giuseppe Vezzoli; Laura Soldati; Maria Svelto; Giovanna Valenti
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

7.  Identification and Functional Characterization of a Novel Mutation in the Human Calcium-Sensing Receptor That Co-Segregates With Autosomal-Dominant Hypocalcemia.

Authors:  Anne Qvist Rasmussen; Niklas Rye Jørgensen; Peter Schwarz
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-25       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.